Modulating the CDC14B-CDH1-PLK1 axis and methods for sensitizing target cells to apoptosis
The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders.
1. A method of sensitizing a cancer cell to apoptosis or cell death comprising contacting the cell with an effective amount of siRNA which has the sequence consisting of SEQ ID NO: 22.
2. A method of sensitizing a cancer cell to apoptosis or cell death comprising contacting the cell with an effective amount of an inhibitor of Cdc14B and an inhibitor of Cdh1.
3. The method of claim 2 , wherein the inhibitor of Cdc14B is an siRNA.
4. The method of claim 2 , wherein the inhibitor of Cdh1 is an siRNA.
5. The method of claim 4 , wherein the siRNA has the sequence consisting of SEQ ID NO: 21.
6. The method of claim 2 , wherein the amount of Plk1 protein in the cell is increased compared to the amount of Plk1 protein in the cell prior to use of the inhibitor.